News

April 9, 2018April 9, 2018

Pfizer and Allogene Agree to Collaborate on Developing Donor-derived CAR T-cell Therapies

News

Pfizer and Allogene Therapeutics have entered into a contribution agreement for Pfizer’s portfolio of assets related to donor-derived chimeric antigen receptor T-cell (CAR T) therapy, a kind of cell ... Read more

April 6, 2018April 6, 2018

Five Prime Doses First Patient With Investigational Antibody FPA150

News

The Phase 1 clinical trial testing FPA150, an investigational antibody targeting the B7-H4 protein, in patients with solid tumors has dosed its first participant, Five Prime Therapeutics announced. Patients eligible for ... Read more

April 5, 2018

French, US Partners to Use Artificial Intelligence to Predict Cancer Treatment Response

News

France’s Institut Curie and the United States’ Freenome company will test whether an artificial intelligence technology focused on blood biomarkers can predict a person’s response to cancer treatment. Checking blood for tumor ... Read more

April 4, 2018April 4, 2018

Apexigen to Recruit Children with Brain Tumors for Phase 1 Trial of Immunotherapy

News

Children with brain tumors that have failed to respond to treatment, or that have returned, will be able to enroll in a Phase 1 clinical trial evaluating an immunotherapy that Apexigen developed. The ... Read more

April 3, 2018April 3, 2018

New Technology that Takes ‘Instagram’ of Immune System May Open Door for Precision Cancer Therapies

News

A new technology that creates a sort of “Instagram” of the immune system may help predict a patient’s response to cancer immunotherapies, researchers say. “What I use here is ... Read more

April 2, 2018April 2, 2018

Early Data Supports Phase 3 Trial of Pegilodecakin as Possible Treatment for Advanced Pancreatic Cancer

News

ARMO Biosciences’ immunotherapy candidate pegilodecakin (AM0010) was seen to be safe in the first interim analysis of a Phase 3 trial evaluating it as a possible treatment of metastatic pancreatic ... Read more

March 29, 2018March 29, 2018

Novartis Joins Harvard and Dana-Farber to Develop Delivery Systems for Immunotherapies

News

Novartis is joining scientists from the Wyss Institute for Biologically Inspired Engineering at Harvard University and the Dana-Farber Cancer Institute to develop biomaterial systems for its portfolio of cancer ... Read more

March 28, 2018

Europe Closer to Approving New Dosing Schedule for Opdivo

News

Following a similar decision in the United States earlier this month, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of ... Read more

March 27, 2018March 27, 2018

New Y-trap Technology Shows Promise as Cancer Immunotherapy

News

A new technology has shown promise in treating several types of tumors in mice that do not respond to cancer immunotherapy medications called checkpoint inhibitors. Results from tests of ... Read more

March 26, 2018March 26, 2018

Venclexta-Rituxan Combo Delays Disease Progression in Lymphocytic Leukemia, Trial Results Show

News

Treatment of patients with relapsed or refractory chronic lymphocytic leukemia with a combination of Venclexta (venetoclax) plus Rituxan (rituximab) significantly extended the time a patient lived without signs of disease ... Read more

Pin It on Pinterest